Paper17548745
Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Heinrichs RW. Arch Gen Psychiatry, 2007. Cited by 37 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Papers, record 17548745. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17548745
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antipsychotic Agents | Major topic |
| Cognition Disorders | Major topic |
| Neuropsychological Tests | Major topic |
| Schizophrenia | Major topic |
| Schizophrenic Psychology | Major topic |
| Chronic Disease | |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Treatment Outcome |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 17,548,746 | Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. | https://conductscience.org/library/papers/17548746 |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,421,073 | Neighborhood environmental deprivation predicts the generalized neurocognitive deficit in schizophrenia. | Schizophr Res | 2026 | https://conductscience.org/library/papers/41421073 | PubMed |
| 40,860,664 | The effects of dance intervention on clinical symptoms and cognitive deficits in hospitalized patients with chronic schizophrenia: a randomized controlled trial. | PeerJ | 2025 | https://conductscience.org/library/papers/40860664 | PubMed |
| 40,545,821 | Enhancement of the left frontoparietal network through real-time functional magnetic resonance imaging functional connectivity-informed neurofeedback and its impact on working memory in schizophrenia: A pilot study. | Psychiatry Clin Neurosci | 2025 | https://conductscience.org/library/papers/40545821 | PubMed |
| 38,672,011 | The Effect of Antipsychotics on Cognition in Schizophrenia-A Current Narrative Review. | Brain Sci | 2024 | https://conductscience.org/library/papers/38672011 | PubMed |
| 37,881,571 | Medial Prefrontal Cortex Dysfunction Mediates Working Memory Deficits in Patients With Schizophrenia. | Biol Psychiatry Glob Open Sci | 2023 | https://conductscience.org/library/papers/37881571 | PubMed |
| 36,648,966 | Cognitive Rehabilitation in Schizophrenia-Associated Cognitive Impairment: A Review. | Neurol Int | 2022 | https://conductscience.org/library/papers/36648966 | PubMed |
| 33,692,676 | The Association Between Metabolic Disturbance and Cognitive Impairments in Early-Stage Schizophrenia. | Front Hum Neurosci | 2020 | https://conductscience.org/library/papers/33692676 | PubMed |
| 33,344,888 | Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. | ACS Pharmacol Transl Sci | 2020 | https://conductscience.org/library/papers/33344888 | PubMed |
| 32,655,348 | Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models. | Front Neurosci | 2020 | https://conductscience.org/library/papers/32655348 | PubMed |
| 32,102,432 | N-(2-Hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1H- benzimidazol-1-yl)propyl]piperidine-4-Carboxamide (D2AAK4), a Multi-Target Ligand of Aminergic GPCRs, as a Potential Antipsychotic. | Biomolecules | 2020 | https://conductscience.org/library/papers/32102432 | PubMed |
| 30,568,606 | Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia. | Front Psychiatry | 2018 | https://conductscience.org/library/papers/30568606 | PubMed |
| 27,578,254 | Time-varying SMART design and data analysis methods for evaluating adaptive intervention effects. | BMC Med Res Methodol | 2016 | https://conductscience.org/library/papers/27578254 | PubMed |
| 27,039,372 | Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. | BMC Psychol | 2016 | https://conductscience.org/library/papers/27039372 | PubMed |
| 25,980,483 | Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study. | Psychopharmacology (Berl) | 2015 | https://conductscience.org/library/papers/25980483 | PubMed |
| 23,785,309 | Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. | Front Neurosci | 2013 | https://conductscience.org/library/papers/23785309 | PubMed |
| 22,584,864 | Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. | Mol Psychiatry | 2012 | https://conductscience.org/library/papers/22584864 | PubMed |
| 22,336,800 | Antipsychotic drug treatment for elderly people with late-onset schizophrenia. | Cochrane Database Syst Rev | 2012 | https://conductscience.org/library/papers/22336800 | PubMed |
| 21,833,224 | Notes from Underground: Are Cognitive-Enhancing Drugs Respecting their Promises? | Front Psychol | 2010 | https://conductscience.org/library/papers/21833224 | PubMed |
| 21,726,569 | Mouse pharmacological models of cognitive disruption relevant to schizophrenia. | Neuropharmacology | 2012 | https://conductscience.org/library/papers/21726569 | PubMed |
| 19,821,380 | Ziprasidone versus other atypical antipsychotics for schizophrenia. | Cochrane Database Syst Rev | 2009 | https://conductscience.org/library/papers/19821380 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17548745
GET https://conductscience.org/api/papers/v1/17548745/cited_by?page=2